As the hCD38 portion of this surrogate can only bind to the human CD38 expressed on the 38C13 tumors, these data suggest that hCD38-mAtt acts directly on the tumor cells but may also indirectly activate immune cell populations. This evidence concerns the gene TMEM79 and neoplasm.